



**RELISH  
PHARMACEUTICALS  
LIMITED**

Office :  
1-2, 4th Floor, Moonlight Complex,  
Opp. Gurukul, Drive-In Road,  
Ahmedabad-380 052, Gujarat, INDIA  
Phone : 079-6652 2247 Fax : 2749 8515

**CIN NO. L24231GJ1993PLC019079**

20<sup>th</sup> January, 2016

To,  
The General Manager-Listing  
Corporate Relationship Department  
The BSE Limited, Ground Floor,  
P.J. Towers, Dalal Street, Mumbai

Scrip Code: 524632

Dear Sir/Madam,

Sub: Compliance with the Regulation 13(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

With reference to above, please find Quarterly Statement of investor Complaints for the Quarter ended December, 2015 in compliance in with the Listing Agreement.

Please take the same on your record and oblige.

Thanking you.

Yours faithfully,

For Relish Pharmaceuticals Limited



Bhoomika Vasavani  
Company Secretary cum Compliance officer  
Encl.: As Above



**RELISH  
PHARMACEUTICALS  
LIMITED**

**CIN NO. L24231GJ1993PLC019079**

Office :  
1-2, 4th Floor, Moonlight Complex,  
Opp. Gurukul, Drive-In Road,  
Ahmedabad-380 052, Gujarat, INDIA  
Phone : 079-6652 2247 Fax : 2749 8515

20<sup>th</sup> January, 2016

To,  
The General Manager-Listing  
Corporate Relationship Department  
The BSE Limited, Ground Floor,  
P.J. Towers, Dalal Street, Mumbai

Ref: Scrip Code: 524632

Dear Sir,

**Sub: - Regulation 13(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015**

Pursuant to Regulation 13(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, the number of investor complaints received and disposed of during the quarter ended December 31, 2015 is given below:

Sr. No.	Particulars	Received
1	Investor Complaints Pending at the beginning of the Quarter as on 1 <sup>st</sup> October, 2015	0
2	Complaints received through Correspondence during of the quarter	0
3	Complaints received from SEBI/SCORES	0
4	Complaints disposed of during the quarter	0
5	Complaints unresolved at the end of quarter	0


The Board/members of the Share Transfer Committee has taken note of the aforementioned Statement at their meeting held on 20<sup>th</sup> January, 2016.

Please take the same on record and acknowledge the receipt of the same.

Thanking you,

Yours faithfully,

For Relish Pharmaceuticals Limited

  
Bhoomika Vasani  
Company Secretary cum Compliance officer